Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular Profiling of Response and Resistance to Venetoclax-Decitabine Therapy in Acute Myeloid Leukemia

Abdullah Khasawneh, Faith Jessica Paran, Rieko Oyama, Abhishek Maiti, Hussein A Abbas, Bofei Wang, Poonam N Desai, Kala Hayes, Joe R Harman, Xiaoping Su, Courtney D. DiNardo, Michael Andreeff, Thomas A Milne, Marina Y. Konopleva, Yoko Tabe

Blood (2023) 142 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2023-180463

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3097–3098.

https://doi.org/10.1182/blood-2022-156999

Published: 2022

Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla

Blood (2022) 139 (6): 907–921.

https://doi.org/10.1182/blood.2021013156

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2021) 138 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2021-154195

Published: 2021

Journal Articles

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

Kotoko Yamatani, Yoko Tabe, Abhishek Maiti, Tomohiko Ai, Kaori Saito, Kazuhiro R Nitta, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Courtney D. DiNardo, Xiaoping Su, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2244.

https://doi.org/10.1182/blood-2021-149432

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Blood (2021) 138 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2021-154279

Published: 2021

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Xiangmeng Wang, Po Yee Mak, Wencai Ma, Xiaoping Su, PhD, Hong Mu, MD PhD, Wenjing Tao, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2018) 132 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2018-99-118367

Published: 2018

Journal Articles

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

Blood (2018) 132 (19): 2100–2103.

https://doi.org/10.1182/blood-2018-05-848473

Published: 2018

Includes: Supplemental data

Journal Articles

Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML

Jianfang Zeng, MD PhD, Alice Soragni, PhD, Jo Ishizawa, MDPhD, Vivian Ruvolo, MS, Christopher B. Benton, MD, Teresa McQueen, MS, Peter Ruvolo, PhD, Yuan Qi, PhD, Xiaoping Su, PhD, Jared Burks, PhD, David S. Eisenberg, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3944.

https://doi.org/10.1182/blood.V128.22.3944.3944

Published: 2016

Journal Articles

Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients

Blood (2016) 128 (22): 597.

https://doi.org/10.1182/blood.V128.22.597.597

Published: 2016

Journal Articles

Developing Therapeutic Strategies for CLL with Mutant p53

Hun Ju Lee, MD, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Huaxian Ma, BS, Alfonso Quintas-Cardama, MD, Yuan Qi, Xiaoping Su, PhD, Sean M. Post, PhD

Blood (2015) 126 (23): 2476.

https://doi.org/10.1182/blood.V126.23.2476.2476

Published: 2015

Journal Articles

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, BS, Carlos E. Bueso-Ramos, MD, Laura Pageon, Mark McArthur, Asha Multani, Aziz Nazha, MD, Taghi Manshouri, PhD, Jan Parker-Thornburg, Peter Hu, Yuan Qi, Xiaoping Su, PhD, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, MD, Joaquin Martinez-López, MDPhD, Sean M. Post, PhD

Blood (2015) 126 (23): 439.

https://doi.org/10.1182/blood.V126.23.439.439

Published: 2015

Journal Articles

PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia

Blood (2015) 125 (23): 3609–3617.

https://doi.org/10.1182/blood-2015-02-626127

Published: 2015

Includes: Supplemental data

Journal Articles

Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia

Polina Matre, PhD, Maryam Shariati, Juliana Velez, Yuan Qi, Sergej Konoplev, MD PhD, Xiaoping Su, PhD, Courtney D. DiNardo, MD, Naval Daver, MD, Ravi Majeti, MD PhD, Michael Andreeff, MD PhD, Steven M. Chan, MD PhD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 3763.

https://doi.org/10.1182/blood.V124.21.3763.3763

Published: 2014

Journal Articles

Genome-Wide Mapping and Subtype Classification of Long Non-Coding RNA in Acute Myeloid Leukemia

Rong Chen, PhD, Gabriel G Malouf, MD PhD, Jianping Zhang, PhD, Xuelin Huang, PhD, John N Weinstein, MD PhD, Jean-Philippe Spano, MD PhD, Jeffrey J. Molldrem, MD, William Plunkett, PhD, Xiaoping Su, PhD

Blood (2014) 124 (21): 2355.

https://doi.org/10.1182/blood.V124.21.2355.2355

Published: 2014

Journal Articles

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Angell Shieh, Ashley F. Ward, Kegan L. Donlan, Emily R. Harding-Theobald, Jin Xu, Charles G. Mullighan, Chao Zhang, Shann-Ching Chen, Xiaoping Su, James R. Downing, Gideon E. Bollag, Kevin M. Shannon

Blood (2013) 121 (24): 4884–4893.

https://doi.org/10.1182/blood-2012-05-432252

Published: 2013

Includes: Supplemental data

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Molecular Profiling of Response and Resistance to Venetoclax-Decitabine Therapy in Acute Myeloid Leukemia

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML

Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients

Developing Therapeutic Strategies for CLL with Mutant p53

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia

Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia

Genome-Wide Mapping and Subtype Classification of Long Non-Coding RNA in Acute Myeloid Leukemia

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only